INS and type 1 diabetes mellitus: For healthcare systems in the global South, where Type 1 Diabetes patients face already poor health outcomes and the production costs of insulin and insulin pumps are high [63, 64], it is expected that limited financial resources, laboratory facilities and specialized personnel required will hinder the manufacturing and administration of cell-based replacement therapies [8].